Page last updated: 2024-12-06

isosorbide-5-mononitrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isosorbide-5-mononitrate (ISMN) is a nitrate-based vasodilator primarily used to treat angina. It is synthesized from isosorbide, a sugar alcohol derived from sorbitol, through nitration. ISMN acts by relaxing blood vessels, reducing the workload on the heart, and improving blood flow to the heart muscles. It is studied for its potential in treating cardiovascular diseases, including angina, heart failure, and pulmonary hypertension. ISMN has been researched extensively for its effects on the cardiovascular system, particularly in the context of chronic heart failure, where it may improve exercise tolerance and reduce hospitalizations. ISMN is an important drug for managing chronic angina, and its long-acting properties allow for effective treatment with less frequent dosing compared to other nitrates.'

isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID27661
CHEMBL ID1311
CHEBI ID6062
SCHEMBL ID26781
MeSH IDM0096187

Synonyms (210)

Synonym
BB 0261072
monocinque
1,4:3,6-dianhydro-5-o-nitro-d-glucitol
isomonit
turimonit
imdur durules
elantan retard
edistol
sorbimon
fem-mono
monodur durules
mononit 20
isomon
ismexin
monisid
glucitol, 1,4:3,6-dianhydro-, 5-nitrate, d-
imdur
ccris 1911
etimonis
monosordil
iturol
mononit 40
monoket retard
ismn stada
olicard
mono mack
mononit
orasorbil
imodur
monocord 50 sr
epicordin
einecs 240-197-2
isosorbide-5-nitrate
monis
sigacora
monosigma
ismn abz
5-ismn
bm 22-145
uniket
ahr 4698
imtrate
mono-mack
vasdilat
vasotrate
elantan long
multitab
elantan
mononit retard 50
percorina
mononitrate d'isosorbide [french]
mono corax
brn 5851319
mono-sanorania
isomonat
conpin
monicor
isopen-20
duride
d-glucitol, 1,4:3,6-dianhydro-, 5-nitrate
ismn basics
ismo-20
mononitrato de isosorbida [spanish]
monolong 40
ismn hexal
un3251
ismn lannacher
ismn heumann
nitramin
plodin
monoclair
monit 20
ismn atid
imazin
monolong 60
1,4:3,6-dianhydro-d-glucitol 5-nitrate
monolong
titarane
olicardin
monoket
ismo
imdur 60
promocard
conpin retardkaps
medocor
mono corax retard
monopront
is 5mn
pertil
monoket od
ismn al
ismn apogepha
monocord 40
isosorbidi mononitras [latin]
nitex
corangin sr
ismox
monizid
monotrate
pentacard 20
monocord 20
ihd ,
corangin
C07714
isosorbide mononitrate
16051-77-7
is 5-mn
isosorbide 5-mononitrate
isosorbide 5-nitrate
ismn
iso-5-mononitrate
is-5mn
NCGC00159334-02
monosorbitrate
is-5-mn
DB01020
isosorbide-5-mononitrate
isosorbide mononitrate (jp17/usp/inn)
ismo (tn)
imdur (tn)
D00630
NCGC00167981-01
CHEBI:6062 ,
monomax
monocord
monocedocard
mononitrate d'isosorbide
monosorb xl 60
isosorbidi mononitras
mononitrato de isosorbida
HMS2093K07
5-isosorbide mononitrate
AKOS005110986
bm 22.145is 5-mnahr-4698
ahr-4698
bm-22145
CHEMBL1311
bm 22.145
diluted isosorbide mononitrate
bm-22.145
nsc-758619
isosorbide dinitrate isosorbide-5-mononitrate
bm-22-145
I0403
[(3s,3ar,6r,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
1,4:3,6-dianhydro-5-o-nitro-d-erythro-hexitol
unii-lx1oh63030
lx1oh63030 ,
isosobide-5-mononitrate [un3251] [flammable solid]
isosobide-5-mononitrate
isosorbide mononitrate [usan:usp:inn:ban:jan]
nsc 758619
d-1,4:3,6-dianhydroglucitol 5-nitrate
1,4:3,6-dianhydrosorbitol 5-mononitrate
LZ43855600
niosh/lz4385560
tox21_111581
dtxsid9023176 ,
dtxcid003176
cas-16051-77-7
pharmakon1600-01503807
nsc758619
S4633 ,
monosorb
isosorbide mononitrate [usp impurity]
isosorbide mononitrate [mart.]
isosorbide dinitrate, diluted impurity c [ep impurity]
isosorbide mononitrate [who-dd]
isosorbide dinitrate isosorbide-5-mononitrate [mi]
isosorbide mononitrate [vandf]
diluted isosorbide mononitrate [usp-rs]
diluted isosorbide mononitrate [usp monograph]
isosorbide mononitrate [jan]
isosorbide mononitrate [orange book]
isosorbide mononitrate [inn]
isosorbide mononitrate [usan]
BRD-K82225283-001-01-5
[(3r,3as,6s,6ar)-6-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[2,3-d]furan-3-yl] nitrate
gtpl7052
CCG-213200
SCHEMBL26781
CS-3495
YWXYYJSYQOXTPL-SLPGGIOYSA-N
W-107977
HY-B0642
AB01563284_01
mfcd00143462
(3r,3as,6s,6ar)-6-hydroxy-hexahydrofuro[3,2-b]furan-3-yl nitrate
AC-8830
SR-05000001872-2
sr-05000001872
SR-05000001872-1
W15583
isosorbide mononitrate 1.0 mg/ml in dimethyl sulfoxide
SBI-0206724.P001
HMS3715I08
Q423401
(3r,3as,6s,6ar)-6-hydroxyhexahydrofuro[3,2-b]furan-3-yl nitrate
isosorbide mononitrate,(s)
isosorbide-mononitrate
NCGC00167981-03
isorbide mononitrate
leicester
EN300-19636279
isosorbide dinitrate, diluted impurity c (ep impurity)
isosorbide mononitrate (usp impurity)
isosorbide mononitrate er
diluted isosorbide mononitrate (usp monograph)
diluted isosorbide mononitrate (usp-rs)
isosorbide mononitrate (mart.)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Transient headache was the most prevalent adverse experience."( Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
Bittar, N; Casareto, R; Chrysant, SG; Danisa, K; Ferraresi, R; Garutti, RJ; Glasser, SP; Ibrahim, R; Shahidi, FE; Watts, LE, 1993
)
0.29
"Hartone is a safe and effective anti-anginal agent comparable to ISMN and is better tolerated."( Safety and efficacy of Hartone in stable angina pectoris--an open comparative trial.
Adhikari, P; Bhat, P; Kumar, PU; Pereira, P, 1999
)
0.3
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Although headache was the most frequent adverse effect in the CR-ISMN group, all symptoms were mild and at self-limiting levels."( Efficacy and safety of controlled-release isosorbide-5-mononitrate in Japanese patients with stable effort angina pectoris.
Daida, H; Kawakubo, K; Kusama, Y; Nakazato, K; Satoh, H; Shimada, K; Sunayama, S, 2006
)
0.6
" Uterine hyperstimulation with fetal heart rate deceleration and other maternal or fetal adverse events are rare but unpredictable."( Outpatient induction -- how safe.
Rath, WH, 2009
)
0.35
" Cardiotoxicity causing angina, arrhythmia and infarction are serious adverse events associated with these agents."( [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB, 2010
)
0.36
"After enrolling 11 patients, the study had to be discontinued due to adverse effects."( Interruption of a study of cervical ripening with isosorbide mononitrate due to adverse effects.
Araujo Júnior, E; Auxiliadora de Aquino, MM; de Silva Bussamra, LC; de Souza, E; Hatanaka, AR; Mattar, R; Moron, AF, 2012
)
0.38

Pharmacokinetics

The possibility of a pharmacokinetic interaction between isosorbide-5-mononitrate (5-ISMN) and epinine, the active metabolite of ibopamine, has been investigated in 8 healthy male subjects.

ExcerptReferenceRelevance
" These results regarding the pharmacokinetic parameters of BM 12."( Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys.
Bartsch, W; Neidlein, R; Pressmar, F; Strein, K, 1992
)
0.28
" Pharmacokinetic modeling of the in vivo time-dependent hemodynamic effects further indicated that the blood compartment data were more consistent with a mechanism of mononitrate action that involves metabolic activation to form nitric oxide and cyclic GMP, rather than direct receptor activation."( Pharmacokinetic/pharmacodynamic relationship of the duration of vasodilating action of organic mononitrates in rats.
Fung, HL; Tzeng, TB, 1992
)
0.28
" The 95% confidence intervals for Cmax and tmax were within the prescribed limits of 70-130%."( [Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms].
Harder, S; Merz, PG; Thürmann, P, 1992
)
0.49
"The possibility of a pharmacokinetic interaction between isosorbide-5-mononitrate (5-ISMN) and epinine, the active metabolite of ibopamine, has been investigated in 8 healthy male subjects given single doses of 200 mg ibopamine and 20 mg 5-ISMN, separately and together."( Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate.
De Sutter, J; De Wilde, G; Duprez, D; Lefebvre, RA; Pocchiari, F; Rosseel, MT, 1992
)
0.76
"The objective of this study was to determine both the pharmacokinetic parameters and the bioavailability of two commercial 20-mg isosorbide-5-mononitrate (IS-5-MN) preparations (test and reference preparation) after single oral administration."( Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers.
Bonn, R; Fritschi, E; Hutt, V; Jaeger, H; Pabst, G; Theodor, R, 1992
)
0.73
" For both formulations, the mean plasma half-life was found to be approximately 5 h after a single dose."( A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
Bron, J; De Jong, AP; Jonkman, JH; Oosterhuis, B; Storm, G; Wittebrood, AJ, 1991
)
0.52
"A pharmacokinetic model is proposed to describe the plasma levels of isosorbidedinitrate (ISDN) and its two pharmacologically active metabolites, isosorbide-2-mononitrate (IS-2MN) and isosorbide-5-mononitrate (IS-5MN), following the oral administration of several 20-mg sustained release formulations of ISDN."( A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
Aldrich, W; Dey, M; Enever, R; Smith, D; Warner, R; Weierstall, R,
)
0.55
" Their terminal elimination half-life is 63, 108 and 264 min respectively."( Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
Schaumann, W, 1989
)
0.54
" We found a wide variation of pharmacokinetic parameters (AUCss0-8 and t1/2) of ISDN, IS-2-N, and IS-5-N in our patients."( Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage.
Boertz, A; Bonn, R; Cawello, W; Dickmans, HA; Evers, J; Weiss, M, 1989
)
0.28
"The pharmacokinetic profile and the bioavailability of a new galenic formulation of isosorbide-5-mononitrate sustained released capsules (Olicard 40 retard) was tested under standardized conditions."( [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
Böttcher, B; Brandt, L; Skutta, T, 1989
)
0.73
"The pharmacokinetic and pharmacodynamic aspects of organic nitrates are discussed, with particular emphasis on the 3 major organic nitrates currently in use, nitroglycerin (NTG), isosorbide dinitrate and isosorbide-5-mononitrate."( Pharmacokinetics and pharmacodynamics of organic nitrates.
Fung, HL, 1987
)
0.46
" On the other hand, perfect dose-linearity of all relevant pharmacokinetic parameters of all three measured isosorbide nitrates was observed for the 20 mg and the 40 mg dose of the capsule."( Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen, H; Leitold, M; Wildfeuer, A, 1988
)
0.27
"Isosorbide 5-mononitrate differs from other clinically used organic nitrate vasodilators because of its almost complete oral absorption, the low intersubject variability in its plasma concentrations and pharmacokinetic parameters, its relatively long half-life and its lack of active metabolites."( Isosorbide 5-mononitrate pharmacokinetics.
Chasseaud, LF, 1987
)
0.27
" Pharmacokinetic data showed that the sustained release formulation reached significantly lower and delayed mean peak plasma levels compared with the conventional formulation, respectively 452."( Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
Assereto, R; Baggio, E; Castoldi, D; Cunietti, E; Gandini, R; Tofanetti, O, 1987
)
0.27
"The aim of the study was to determine the relative bioavailability and the pharmacokinetic parameters following administration of a slow-release formulation of isosorbide dinitrate (ISDN, Isdin) capsules (20, 40 and 60 mg)."( [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Gielsdorf, W; Jaeger, H; Loew, D; Lutz, VD; Rasper, J, 1985
)
0.46
" Pharmacokinetic calculations based on plasma concentrations should be viewed with caution, as the data on which these calculations are based are often very limited, and the very rapid disappearance of for example glyceryl trinitrate from plasma makes the choice of an appropriate kinetic model and exact calculations difficult."( Clinical pharmacokinetics of organic nitrates.
Bogaert, MG,
)
0.13
" These results provide an interesting example of divergent pharmacokinetic interactions exhibited by two isomeric metabolites."( Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
Fung, HL; Morrison, RA, 1984
)
0.27
" A two-compartment open model was taken as a basis for the calculations of the plasma concentration curves and the pharmacokinetic parameters."( Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.
Steudel, AT; Steudel, HC; Volkenandt, M, 1983
)
0.59
"The aim of this study was to determine pharmacokinetic data of isosorbide-5-mononitrate (IS-5-MN) in dogs and to correlate them with the hemodynamic effects of this drug."( Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs.
Bartsch, W; Dietmann, K; Endele, R; Kühnle, HF; Sponer, G; Strein, K, 1984
)
0.8
"The present comparative pharmacokinetic study performed to establish the relative bioavailability for an isosorbide dinitrate (ISDN) retard preparation (Sorbidilat-retard) included 6 healthy, male and female volunteers."( [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Degen, J; Geigenberger, A; Maier-Lenz, H, 1982
)
0.26
"The steady-state pharmacokinetic profile of isosorbide-5-mononitrate (5-ISMN) after oral administration of an extended-release tablet formulation of 5-ISMN 60 mg or 120 mg once a day was compared with that after administration of isosorbide dinitrate (ISDN) 40 mg every 6 hours, in a randomized, open-label, three-way crossover trial in 24 healthy men."( Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Affrime, MB; Christopher, D; Cohen, A; Kosoglou, T; Patrick, JE; Radwanski, E,
)
0.72
" Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied."( Clinical pharmacokinetics of nitrates.
Bogaert, MG, 1994
)
0.29
" Pharmacokinetic parameters of the drug was obtained from the human serum level-time curve measured."( [Gas chromatographic method with EC detection to determine isosorbide-5-mononitrate (IS-5-MN) in human serum and its pharmacokinetic parameters].
Dong, SN; Fu, YK; Li, R; Xia, GZ, 1994
)
0.53
" There were no significant differences in the pharmacokinetic parameters for IS-5-MN between the LCFD and the HCFD."( Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
Inoue, K; Kuroda, T; Nii, T; Sata, H, 1997
)
0.3
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3
" Pharmacokinetic data showed that with the test tablet significantly lower and delayed mean peak plasma levels (Cmax) were reached compared with the reference preparation in both single and multiple dose studies."( Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
Fu, L; Huang, X; Ji, P; Wei, S; Yan, B; Zhang, Q, 1998
)
0.51
" The major pharmacokinetic parameters of domestic and imported 5-IM sustained-release capsule with a 5-d multiple dose were respectively: Cmax (677 +/- 103) and (702 +/- 76) micrograms."( Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men.
Ding, Y; Huang, DK; Jiang, ZH; Luo, JP; Luo, WX; Peng, JH; Qiu, J; Shen, JP; Sheng, LS; Zhang, YD, 1999
)
0.3
" The pharmacokinetic characteristics of 5-ISMN in ten human volunteers after a single oral dose of 20 mg 5-ISMN were investigated."( [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
Yang, LL; Yuan, YS; Zhao, FL, 1997
)
0.63
"The pharmacokinetic parameters of two oral formulations of 20 mg tablets of isosorbide-5-mononitrate (CAS 16051-77-7, Dilavenil as test and another commercially available preparation as reference) were compared in an open-label, randomized, single oral dose, two-period cross-over design in 20 healthy volunteers under fasting conditions."( Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
Daftsios, AC; Nikolaidis, N; Niopas, I, 2002
)
0.77
" Pharmacokinetic data showed that the sustained release formulation reached mean peak plasma levels significantly later and lower minimum plasma concentration (Cmin), compared with the conventional preparation."( [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Fu, L; Huang, X; Ji, P; Wei, S; Yan, B; Zhang, Q, 1998
)
0.51
" Various pharmacokinetic parameters including AUC0-t, AUC0-infinity, Cmax, tmax, t1/2, Kelm and MRT were determined for the three formulations and found to be in good agreement with literature values."( Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
Cai, L; Chen, J; Gao, KP; Jiang, XG; Lu, W; Shi, ZQ; Zhang, QZ, 2004
)
0.32
"The difference found in the Cmax and AUC(SS)/kg of isosorbide-5-mononitrate between male and female subjects must be due to the difference in dose/kg, following a standard dose of 60 mg."( Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Dammers, E; Valducci, R; Vree, TB, 2004
)
0.83
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic assessments were taken at regular intervals over 24 h after dosing on the last day of each treatment period."( Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Antunes, A; Bartlett, M; Dieterich, HA; Dole, WP; Howard, D; Vaidyanathan, S; Yeh, CM, 2008
)
0.56
" And then this method was successfully applied to a pharmacokinetic investigation on isosorbide dinitrate oral spray in healthy volunteers."( A simple and sensitive gas chromatography method for determination of isosorbide dinitrate and its metabolites in human plasma: application to pharmacokinetics study on oral spray.
Guo, J; Guo, R; Jiang, Z; Li, R; Sun, Z; Wei, C; Yuan, G; Zhang, R, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
"The aim of this study was to investigate the effect of the nitric oxide donor isosorbide-5-mononitrate (5-ISMN) alone or in combination with the natural hepatoprotectant with anti-oxidant activity silymarin on the carbon tetrachloride (CCl(4))-induced hepatic injury in rats."( Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats.
Abdel Salam, OM; Shafee, N; Sleem, AA, 2010
)
0.84
" Administered with losartan 100 mg or alone, ISMN lowered AIx, demonstrating that acute effects of a nitrate donor are much larger than those of an ARB even when administered with an ARB."( Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure.
Bolognese, JA; Feig, PU; Herman, GA; Kaufman, R; McCarthy, JM; Miller, DL; Nunes, I; Salotti, D; Smith, WB,
)
0.13

Bioavailability

slow-release isosorbide-5-mononitrate is unaffected by food, but there is a slower rate of absorption.

ExcerptReferenceRelevance
" The total bioavailability of BM 12."( Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys.
Bartsch, W; Neidlein, R; Pressmar, F; Strein, K, 1992
)
0.28
" The relative bioavailability of ISDN applied buccally, however, was more than twice that after oral application."( [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
Keller-Stanislawski, B; Marschner, JP; Rietbrock, N, 1992
)
0.28
"The bioavailability of 3 different commercial available isosorbide mononitrate (IS-5-MN; CAS 16051-77-7) 40 mg slow-release preparations (A, B and reference formulation C) was determined after oral application to 18 healthy volunteers in a randomized cross-over study."( [Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms].
Harder, S; Merz, PG; Thürmann, P, 1992
)
0.49
"The objective of this study was to determine both the pharmacokinetic parameters and the bioavailability of two commercial 20-mg isosorbide-5-mononitrate (IS-5-MN) preparations (test and reference preparation) after single oral administration."( Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers.
Bonn, R; Fritschi, E; Hutt, V; Jaeger, H; Pabst, G; Theodor, R, 1992
)
0.73
" ISDN bioavailability was higher after morning than after evening administration and hemodynamic effects were more pronounced in the evening than in the morning."( Chronopharmacology of oral nitrates in healthy subjects.
Lemmer, B; Scheidel, B, 1991
)
0.28
"Assessment of Bioavailability of Organic Nitrates/Comparative bioavailability study of sustained-release isosorbide dinitrate preparations."( [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
Babej-Dölle, RM; Blume, H; Scheidel, B; Siewert, M; Stenzhorn, G, 1991
)
0.28
" This model is of particular usefulness as a formulation tool in designing sustained release ISDN formulations of the type investigated here since the observed first-order absorption rate constant correlates well with the in vitro first-order dissolution rate constant."( A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
Aldrich, W; Dey, M; Enever, R; Smith, D; Warner, R; Weierstall, R,
)
0.36
" A significant loss in relative bioavailability was observed for (A) with 82."( [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
Bonn, R; Muck, B; Rietbrock, N, 1989
)
0.52
" In a three-period change-over study, two other commercial SR preparations exhibited only 79% and 53% of the bioavailability of the new formulation, which was significant in both cases."( Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).
Akpan, W; Jaeger, H; Lutz, D; Mosberg, H; Neugebauer, G; Stemmle, B, 1989
)
0.54
"The pharmacokinetic profile and the bioavailability of a new galenic formulation of isosorbide-5-mononitrate sustained released capsules (Olicard 40 retard) was tested under standardized conditions."( [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
Böttcher, B; Brandt, L; Skutta, T, 1989
)
0.73
" In the rat 3 shows a bioavailability and an acute toxicity inferior to those of 5-ISMN after oral administration."( New isosorbide 5-mononitrate derivative with hypotensive activity.
Borella, F; Comini, A; Coppi, G; Dall' Asta, L; Gatti, MT, 1989
)
0.28
" In terms of areas under the curve, the mean bioavailability of the 40 mg sustained release capsule relative to the reference formulation was 198% with respect to ISDN, and 197% both with respect to IS-2-N and IS-5-N."( Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen, H; Leitold, M; Wildfeuer, A, 1988
)
0.27
" Bioavailability of slow-release isosorbide-5-mononitrate is therefore unaffected by food, but there is a slower rate of absorption."( The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
Green, ST; Miller, SH; Thomson, AH; Whiting, B, 1988
)
0.81
" The results indicate that a well-absorbed substance such as isosorbide-5-nitrate is absorbed from the stomach and small intestinal in a manner that is controlled by the properties of the pellets."( Investigation of the gastrointestinal transit and in vivo drug release of isosorbide-5-nitrate pellets.
Boertz, A; Cawello, W; Cordes, G; Davis, SS; Fischer, W; Khosla, R; Sandrock, K, 1987
)
0.27
" The sustained release preparations showed a low loss of bioavailability of 13-19% as compared to the nonretarded standard formulations."( [Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate].
Gracien, E; Heidemann, R; Menke, G; Rietbrock, N, 1987
)
0.27
"Isosorbide 5-mononitrate (IS 5-MN) has favourable pharmacodynamic properties, such as the specific half-life (close to 5 h) and the bioavailability (100% after oral ingestion)."( Oral isosorbide 5-mononitrate can protect from myocardial ischemia induced by ergonovine test and by isometric effort. Preliminary results from an echocardiographic acute study in anginal patients.
Distante, A; L'Abbate, A; Lombardi, M; Morales, MA; Moscarelli, E, 1987
)
0.27
"The relative bioavailability of isosorbide dinitrate (ISDN) and its mononitrate metabolites (IS-2-MN, IS-5-MN) was determined under repetitive dose conditions in 8 healthy volunteers using a randomised, crossover design."( [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
Knoll, J; Menke, G; Merz, PG; Rietbrock, N, 1985
)
0.53
"The aim of the study was to determine the relative bioavailability and the pharmacokinetic parameters following administration of a slow-release formulation of isosorbide dinitrate (ISDN, Isdin) capsules (20, 40 and 60 mg)."( [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Gielsdorf, W; Jaeger, H; Loew, D; Lutz, VD; Rasper, J, 1985
)
0.46
"We studied the kinetics of isosorbide dinitrate (ISDN) after a dose of 5 mg iv and the bioavailability of a sublingual and an oral preparation of ISDN."( Isosorbide dinitrate bioavailability, kinetics, and metabolism.
Galeazzi, RL; Straehl, P, 1985
)
0.27
" It has also proved valuable in determining the relative bioavailability of representatives of this class of drugs."( Digital pulse plethysmography--a tool for investigating vasoactive substances.
Neugebauer, G; von Möllendorff, E, 1985
)
0.27
"The relative bioavailability of isosorbide-5-mononitrate from two different formulations (MONOCLAIR, ISMO) was investigated in a double-blind randomized cross-over study in 8 healthy human subjects."( Pharmacokinetics and bioavailability of isosorbide-5-mononitrate in humans.
Bacher, S; Eichler, HG; Horwatitsch, H; Rameis, H, 1985
)
0.82
" After oral administration, plasma concentrations are very low; with sublingual or cutaneous administration, higher plasma concentrations can be obtained, suggesting a high first-pass extraction after oral administration, but quantitative data on bioavailability are lacking."( Clinical pharmacokinetics of organic nitrates.
Bogaert, MG,
)
0.13
" At a dose of 2 mg/kg, the oral bioavailability of ISDN was found to be about 40%."( Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
Fung, HL; Morrison, RA, 1984
)
0.27
"The relative bioavailability of isosorbide-5-mononitrate (IS-5-MN) has been determined after a 3-day period of dosing with 20 mg in standard-release reference tablets and sustained-release capsules at 12-h intervals, 40 mg in sustained-release capsules (Olicard 40 retard) at 24-h intervals and after single oral dose of 60 mg sustained-release capsules (Olicard 60 retard), in a cross-over study with 12 human subjects."( [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
Chasseaud, LF; Cook, SC; Darragh, A; Lambe, RF; Leaf, FC; Major, RM; Taylor, T, 1984
)
0.87
"Plasma concentrations and bioavailability of isosorbide dinitrate (ISDN) and its active metabolites isosorbide 2-mononitrate (2-ISMN) and isosorbide 5-mononitrate (5-ISMN) from two sustained-release formulations and one standard-release formulation of isosorbide dinitrate were compared."( Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud, LF; Darragh, A; Doyle, E; Lambe, RF; Taylor, T, 1983
)
0.27
" The bioavailability of isosorbide dinitrate from this sustained-release formulation was about 90% of that from a standard formulation."( Newer aspects of the pharmacokinetics of organic nitrates.
Chasseaud, LF, 1983
)
0.27
"The pharmacokinetics and bioavailability of IS-5-MN after single-dose oral and intravenous application were investigated over 24 h in three patients with liver cirrhosis and compared with normal subjects."( Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.
Steudel, AT; Steudel, HC; Volkenandt, M, 1983
)
0.59
" From the comparison of the areas under the curve, a bioavailability of 71."( Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs.
Bartsch, W; Dietmann, K; Endele, R; Kühnle, HF; Sponer, G; Strein, K, 1984
)
0.56
"The present comparative pharmacokinetic study performed to establish the relative bioavailability for an isosorbide dinitrate (ISDN) retard preparation (Sorbidilat-retard) included 6 healthy, male and female volunteers."( [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Degen, J; Geigenberger, A; Maier-Lenz, H, 1982
)
0.26
"We evaluated the effect of a high-fat breakfast and gastric emptying rate on the oral bioavailability of a isosoribide-5-mononitrate (5-ISMN) controlled-release tablet formulation (IMDUR 60-mg tablets, Astra Hässle AB, Mölndal, Sweden) relative to an oral solution in 18 healthy men."( Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet.
Affrime, MB; Christopher, D; Flannery, BE; Heimark, L; Kazierad, DJ; Kosoglou, T; Patrick, JE; Radwanski, E; Schentag, JJ, 1995
)
0.55
" The relative bioavailability with respect to a reference preparation for AUC related to isosorbide dinitrate was 107."( [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].
Buchberger, D; Häring, N; Läuter, J; Metzner, JE, 1997
)
0.3
"The aim of this study was to investigate the bioavailability of isosorbide mononitrate (IS-5MN) after oral administration of Monocard 20 mg-capsules, made in "Synteza" â Pharmaceutical-Chemical Company in Poznań."( [The evaluation of the bioavailability of isosorbide 5-mononitrate].
Drobnik, L; Dyderski, S; Szkutnik, D; Szymańska-Shawkat, E, 1999
)
0.3
"The bioavailability of IS-5MN after oral administration of Monocard 20 mg is the same as after oral administration of Effox 20 mg, whose clinical efficacy was tested before."( [The evaluation of the bioavailability of isosorbide 5-mononitrate].
Drobnik, L; Dyderski, S; Szkutnik, D; Szymańska-Shawkat, E, 1999
)
0.3
" The relative bioavailability of the domestic capsule for single and multiple dose were 96% +/- 11% and 98% +/- 10%, respectively."( Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men.
Ding, Y; Huang, DK; Jiang, ZH; Luo, JP; Luo, WX; Peng, JH; Qiu, J; Shen, JP; Sheng, LS; Zhang, YD, 1999
)
0.3
"The purpose of this study was to evaluate the relative bioavailability and bioequivalence of a test and a reference sublingual tablet each containing 5 mg of isosorbide dinitrate in healthy volunteers."( Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
Daftsios, AC; Nikolaidis, N; Niopas, I, 2001
)
0.31
"From the results of the present study, it is concluded that the test and reference isosorbide dinitrate sublingual preparations are bioequivalent in both extent and rate of absorption and it can be assumed that they are therapeutically equivalent and exchangeable in clinical practice."( Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
Daftsios, AC; Nikolaidis, N; Niopas, I, 2001
)
0.31
"1), with a relative bioavailability of 108."( [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Fu, L; Huang, X; Ji, P; Wei, S; Yan, B; Zhang, Q, 1998
)
0.51
" 3178 +/- 769 ng x ml(-1) x h, respectively, and the relative bioavailability of 5-ISMN tablet was 105 +/- 20%."( Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
Cai, L; Chen, J; Gao, KP; Jiang, XG; Lu, W; Shi, ZQ; Zhang, QZ, 2004
)
0.32
"We sought to determine if the nitric oxide (NO) donor isosorbide mononitrate (ISMN) (200 mg/kg body weight/day) decreases vascular bioavailability of superoxide in atherosclerosis."( Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate.
Kojda, G; König, I; Meyer, W; Müller, S, 2004
)
0.32
"Vascular oxidative stress limits the bioavailability of endothelial NO and promotes atherosclerosis, while NO itself exerts antioxidative effects."( Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate.
Kojda, G; König, I; Meyer, W; Müller, S, 2004
)
0.32
"These data suggest that eccentric ISMN can completely inhibit the increase of vascular bioavailability of superoxide and partially prevent intimal lesion formation and endothelial dysfunction in hypercholesterolemia."( Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate.
Kojda, G; König, I; Meyer, W; Müller, S, 2004
)
0.32
" The failure of synthesis and/or the lost of nitric oxide bioavailability is the major feature of endothelial dysfunction and key factor initiating progression of atherosclerosis."( [Endothelium and nitric oxide].
Garaliene, V, 2008
)
0.35
" Furthermore, the dog pharmacokinetics and relative bioavailability of the test formulation (5-ISMN MOTS) have been compared with the reference formulation (Imdur: 60 mg/tablet, a sustained release, SR, tablet system) following an oral single dose of 60 mg given to each of six Beagle dogs."( Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo.
Bi, K; Chen, X; Duan, X; Liu, Q; Luo, G; Wang, Y; Zhang, Y, 2009
)
0.6
"1 h in vivo, which had a good consistency with the in vitro results, and the relative bioavailability was nearly 100% comparing to the normal tablets."( Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate.
Dai, Q; Liu, S; Liu, Y, 2009
)
0.58
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The objective of the present study was to develop a novel in vitro system to simulate the process of dissolution and permeation of oral solid dosage forms in vivo, and to establish a correlation between in vitro permeation and in vivo absorption that could predict the bioavailability (BA) and bioequivalence (BE) of congeneric products."( Study on dissolution and absorption of four dosage forms of isosorbide mononitrate: level A in vitro-in vivo correlation.
Gao, X; Gu, H; He, X; Ji, RF; Li, ZQ; Sun, SJ; Wang, YF; Xu, YY, 2011
)
0.37
" The relative bioavailability of the osmotic-pump tablets against the reference formulation in single and multiple dose regimens was 116."( In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release.
Chi, Q; Du, L; Jiang, Q; Li, X; Wang, C, 2012
)
0.62
" The relative bioavailability of the ICR tablets compared to the reference formulation in the single and multiple dose regiments were 90."( Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation.
Du, L; Jiang, Q; Li, M; Li, X; Li, Y, 2014
)
0.64
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Oral treatment with isosorbide-5-mononitrate (IS-5.MN; 5 mg kg-1) indicative of the induction of tolerance to GTN but not to SIN-1.

ExcerptRelevanceReference
" An asymmetrical dosage regimen of isosorbide mononitrate has been shown to provide antianginal efficacy for at least 12 hours."( Pharmacokinetics of isosorbide mononitrate.
Abshagen, UW, 1992
)
0.28
"To avoid the development of nitrate tolerance secondary to relatively constant elevated plasma nitrate concentrations, intermittent nitrate dosing has been advocated."( Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation.
Allgén, J; Amtorp, O; Nyberg, G; Olsson, G; Parker, JO, 1992
)
0.28
"Rats dosed orally with isosorbide dinitrate (1 mg kg-1) were exposed to smoke from standard and nicotine-reduced cigarettes for 8 min using a smoking machine."( Influence of standard and nicotine-reduced cigarette smoke on plasma concentrations of isosorbide dinitrate and its metabolites in rats.
Araki, Y; Furuno, K; Gomita, Y, 1991
)
0.28
" ST-depression at comparative work load at 2 h after dosing was reduced by 49% acutely after administration of IS-5-MN."( Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris.
Krepp, HP, 1991
)
0.51
" Ten patients under each dosage were completely freed from attacks."( Sustained-release IS-5-MN in the treatment of coronary heart disease.
Keck, M, 1991
)
0.28
" In steady state during multiple dosing (t."( A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
Bron, J; De Jong, AP; Jonkman, JH; Oosterhuis, B; Storm, G; Wittebrood, AJ, 1991
)
0.52
" HPLC and TLC-densitometry are considered for the determination of 5-ISMN: lactose and pharmaceutical dosage forms."( New methods for the assay of 5-isosorbide mononitrate and its validation.
Azcona, T; Garcia de Mirasierra, M; Grau, C; Martin-Gonzalez, A; Pascual, C; Zamorano, P, 1991
)
0.28
" This anti-anginal effect persists during long-term treatment without the development of tolerance; once-daily treatment produces a plasma nitrate profile that is high enough to give anti-anginal protection during the daytime, but low enough during the latter part of the dosage interval to avoid the development of tolerance."( Clinical experience with Imdur in angina pectoris. A review.
Nyberg, G, 1990
)
0.28
" Isosorbide-5-mononitrate prolonged treadmill walking time 4, 8 and 12 h after morning dosing by 54, 41 and 52 s, but these changes were not significant compared to placebo."( Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
Parker, JO, 1991
)
1.52
" The data provide evidence of circadian phase-dependency in the dose-response relationship of oral IS-5-MN."( Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.
Becker, HJ; Blume, H; Lemmer, B; Scheidel, B, 1991
)
0.53
" Long-term therapy with 3 x 20 mg of ISDN or IS-5-N daily over 4 weeks does not induce tolerance, whereas the dosage of 3 x 60 mg ISDN resp."( Pulmonary arterial pressure and working capacity as parameters for checking the development of tolerance under nitrate therapy.
Jansen, W; Tauchert, M, 1990
)
0.28
" Our results show that an oral dosage of 20 mg of 5-IM given to patients with stable angina pectoris increased the capacity and exercise tolerance delaying significantly the onset time of angina, the onset time of EKG ischemia and its decree induced by the effort up to 5 hours after its administration."( [Changes in exercise capacity and in induced ischemia with an oral dose of 5 isosorbide mononitrate in patients with stable angina pectoris].
Avila Escribano, C; Cascón Bueno, M; Diego Domínguez, M; Fernández Esteban, T; Martín Luengo, C; Nieto Ballesteros, F; Pavón Osuna, P; Santos Rodríguez, I, 1990
)
0.28
" Many studies with oral dosing of isosorbide dinitrate or isosorbide-5-mononitrate at least three times daily have proven nitrate tolerance in patients with coronary artery disease and/or congestive heart failure."( Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.
Silber, S, 1990
)
0.73
" An important indicator for the effect achievable for a certain dose or for the necessary dosage to affect a defined reduction in ventricular filling pressures, is the magnitude of right atrial pressure."( [Nitrates in the treatment of heart failure].
Dirschinger, J; Hall, D; Rudolph, W, 1990
)
0.28
" The dosage was similar in subsets I to IV (8."( Intravenous isosorbide-5-mononitrate in the treatment of acute myocardial infarction.
Batinić, Z; Goldner, V; Pavicić, L; Rezaković, DE; Stalec, J; Weiss, M, 1990
)
0.66
" At 12 hours, the 100-mg dosage still amounted to greater than 50% of its maximum and was significantly more marked than the 50 mg dose."( Long-acting, marked antiischemic effect maintained unattenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained-release form.
Beyerle, A; Reiniger, G; Rudolph, W, 1990
)
0.49
"Repeated treadmill exercise tests were used in 20 patients with stable exercise-induced angina in order to comparatively examine various dosage forms of isosorbide-5-mononitrate (IMN) and isosorbide dinitrate (ID) during their single administration."( [A new antianginal preparation: isosorbide-5-mononitrate].
Blagodatskikh, SV; Egorov, LV; Martsevich, SIu; Metelitsa, VI; Simkhaev, LS; Slastnikova, ID, 1990
)
0.76
" To assess their antiplatelet properties in vivo and to compare time and dosage requirements, we infused both IS-2-MN and IS-5-MN for 30 minutes, on 2 separate days, into nine patients with stable coronary artery disease, at rates of 4 mg/hr (n = 4) and 8 mg/hr (n = 5)."( Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects.
Bernini, W; De Caterina, R; Giannessi, D; Lazzerini, G; Lombardi, M; Mazzone, A; Moscarelli, E; Weiss, M, 1990
)
0.28
" The peripheral arterial and venous effects of IS-5-MN during the first and last dosing interval were followed by changes in the finger pulse curve, standing systolic blood pressure, heart rate, and venous distensibility."( Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.
Jähnchen, E; Siefert, F; Trenk, D; Wagner, F, 1990
)
0.52
" Dose-response curves for the relaxing and cyclic guanosine monophosphate (cGMP) increasing effects of nicorandil were obtained in isolated strips of bovine coronary arteries and compared with those of other nitrovasodilatators."( Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.
Holzmann, S; Kukovetz, WR, 1987
)
0.27
" For isosorbide dinitrate and isosorbide 5-mononitrate, as well as for transdermal nitroglycerin systems, interval treatment dosing regimens with maintained effectiveness documented in controlled studies have been delineated."( Effectiveness of interval nitrate therapy in angina pectoris.
Bayeric, A; Dirschinger, J; Hall, D; Reiniger, G; Rudolph, W, 1989
)
0.28
" Results indicate a circadian phase-dependency in the dose-response relationship of oral nitrates."( Clinical chronopharmacology of oral nitrates.
Becker, HJ; Blume, H; Grether, D; Lemmer, B; Lenhard, G; Renczes, J; Scheidel, B; Stenzhorn, G, 1989
)
0.28
" Dosing regimens with documented effectiveness in long-term controlled studies are available for both isosorbide dinitrate and isosorbide 5-mononitrate as well as for transdermal nitroglycerin systems."( [Long-term therapy with nitrates. How can continuous effectiveness be achieved?].
Beyerle, A; Dirschinger, J; Reiniger, G; Rudolph, W, 1989
)
0.28
"A differential pulse polarographic method requiring little sample separation was developed for the determination of isosorbide-5-mononitrate in tablet dosage form with the standard addition technique and without interference from common excipients."( Determination of isosorbide-5-mononitrate in tablets by differential pulse polarography.
Giannellini, V; Gratteri, P; La Porta, E; Papeschi, G; Pinzauti, S, 1989
)
0.83
" Its pharmacokinetics are linear over the dosage range likely to be used clinically."( Isosorbide 5-mononitrate pharmacokinetics.
Chasseaud, LF, 1987
)
0.27
"This article reviews the development and pharmacokinetics of a number of new dosage formulations (e."( Various administration forms of nitrates and their possibilities.
Jonsson, UE, 1987
)
0.27
" After receiving treatment for 2 weeks with isosorbide dinitrate retard at a dosage of 2 or 3 tablets per day, only those patients continued the study who had a weekly average of 4 or more anginal attacks during this basal period."( Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study.
Bidoggia, H, 1987
)
1.72
"The efficacy of the isosorbide mononitrate preparations ISMN-20 (elantan 20) and ISMN-50 (elantan long) and the influence of the time of dosage on the quality of life was investigated in 3624 patients with the clinical diagnosis coronary heart disease and stable angina pectoris in an open multi-center trial."( [The effect of time and dosage of isosorbide mononitrate on objective and subjective parameters in angina pectoris].
Herrmann, H; Kuhl, A; Maier-Lenz, H, 1988
)
0.27
" At the studied dosage there was a linear relationship between dose and serum concentration of ISDN and its two metabolites in the proportion of 1:6:70."( [Dose-dependent serum concentration of ISDN and its metabolites following administration of ISDN-retard. Studies under steady-state conditions].
Burkhardt, H; Deuster, U; Loew, D; Rietbrock, N, 1986
)
0.27
" This naturally long-acting metabolite in ISDN works usually with a standard dosage of 20 mg twice daily."( Oral isosorbide-5-mononitrate: pharmacokinetics and clinical efficacy.
Kanto, JH, 1987
)
0.79
" Isosorbide 5-mononitrate appears at least as effective as the same dosage of isosorbide dinitrate and is probably superior to the calcium antagonists."( Mononitrates as monotherapy in the prophylactic treatment of angina pectoris.
Aberg, A; Aström, H; Carlens, P; Lindström, E; Lundman, T; Nordlander, R; Nyberg, G; Rehnqvist, N; Ulvenstam, G, 1987
)
0.27
" After a 2-week placebo period ISMN was administered in a single-blind fashion with the dosage being titrated at 2-week intervals."( Isosorbide-5-mononitrate--effective monotherapy in chronic stable angina.
Akhras, F; Jackson, G; Jefferies, S, 1985
)
1.71
" ISDN bioavailability after oral (10 mg) or sublingual dosing (10 mg) was similar (about 29%), indicating that the first-pass effect cannot be avoided by sublingual ISDN dosing."( Isosorbide dinitrate bioavailability, kinetics, and metabolism.
Galeazzi, RL; Straehl, P, 1985
)
0.27
" The 14-day therapy with elantan 20 in a dosage of 3 X 1 tabl."( [Treatment of coronary disease with elantan. Results of a multicenter study].
Haase, W; van Hasselt, P; Weiss, M, 1984
)
0.27
" The log dose-response curve of ISDN in rabbit aortic rings was constructed in the absence and presence of three fixed concentrations of 5-ISMN (5 X 10(-6), 10(-5), and 3 X 10(-5) M)."( Effect of 5-isosorbide mononitrate on isosorbide dinitrate-induced relaxation of rabbit aortic rings.
Bennett, BM; Brien, JF; Marks, GS; Nakatsu, K; Tam, GS; Van Alstyne, K, 1984
)
0.27
"The relative bioavailability of isosorbide-5-mononitrate (IS-5-MN) has been determined after a 3-day period of dosing with 20 mg in standard-release reference tablets and sustained-release capsules at 12-h intervals, 40 mg in sustained-release capsules (Olicard 40 retard) at 24-h intervals and after single oral dose of 60 mg sustained-release capsules (Olicard 60 retard), in a cross-over study with 12 human subjects."( [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
Chasseaud, LF; Cook, SC; Darragh, A; Lambe, RF; Leaf, FC; Major, RM; Taylor, T, 1984
)
0.87
" It was concluded that the transdermal dosage form of ISDN, which possesses a more prolonged pharmacologic effect than the oral dosage form, may be useful in the prevention and cure of angina pectoris."( [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
Kimura, T; Kogi, K; Saito, T; Tanaka, O, 1982
)
0.26
" Furthermore, the choice of only one antiischemic drug at a fixed dosage may not be aggressive enough in suppressing ischemia completely."( [Isosorbide-5-mononitrate in silent ischemia].
Brandt, D; Dorda, W; Pichler, M; Teubl, H, 1995
)
1.2
"Eighteen patients with acute myocardial infarction (AMI) followed the same extended-release isosorbide 5-mononitrate dosage regimen as was used in the Fourth International Study of Infarct Survival (ISIS-4)."( The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
Held, P; Hornestam, B; Jonsson, UE; McClennen, W, 1995
)
0.29
"Isosorbide-5-mononitrate (IMN) concentration-antianginal effect relationships were studied in 14 coronary heart diseases patients with stable exertion-induced angina after administration of Efox (Schwarz-Pharma) as two dosage forms: routinely acting tablets (20 mg) and long-acting capsules (50 mg)."( [The relationship between the isosorbide-5-mononitrate concentration and its antianginal effect following the administration of regular and prolonged-action drug forms in patients with stenocardia of effort].
Blagodatskikh, SV; Kozyreva, MP; Kutishenko, NP; Martsevich, SIu; Metelitsa, VI; Simkhaev, LS; Slastinkova, ID; Vakulovskaia, MK,
)
1.86
" Simple, well-designed dosing schedules can avoid tolerance and rebound phenomena and can improve patient compliance."( The rationale for nitrates in angina pectoris.
Held, P; Olsson, G, 1995
)
0.29
" Appropriate dosing regimens of controlled-release formulations of isosorbide dinitrate (ISDN) and controlled-release NTG during long-term therapy have not been established."( Short and long-acting oral nitrates for stable angina pectoris.
Lipicky, RJ; Thadani, U, 1994
)
0.29
"Thirty-seven patients with chronic, stable angina pectoris were included in a randomized, double-blind cross-over study to assess the efficacy of once- and twice-daily dosage regimens of 60 mg isosorbide-5-mononitrate, in a controlled-release formulation (5-ISMN Durules, Astra)."( Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
Nordlander, R; Walter, M, 1994
)
0.72
" There was no increase in nocturnal angina during eccentric dosing with IS-5-MN."( Eccentric dosing with isosorbide-5-mononitrate in angina pectoris.
Parker, JO, 1993
)
0.6
" The aim of the study was to determine whether or not an asymmetric dosing regimen was being followed by the patients."( Compliance as a factor in the development of nitrate tolerance: a patient investigation.
Löfdahl, P,
)
0.13
" dosing schedule) oral treatment with isosorbide-5-mononitrate (IS-5-MN; 5 mg kg-1) indicative of the induction of tolerance to GTN but not to SIN-1."( Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies.
Mollace, V; Pistelli, A; Salvemini, D, 1993
)
0.56
" The beneficial nitrate effect can be preserved by appropriate dosing which provides a period of many hours of nitrate washout during each 24 h period."( Nitrate tolerance--problems both new and old.
Parker, JO, 1996
)
0.29
"In a randomized, double-blind, crossover study, 89 patients with stable angina pectoris were studied to compare two different dosage strategies of isosorbide-5-mononitrate (5-ISMN)."( Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group.
Cleophas, TJ; Niemeyer, MC; van der Meulen, J; van der Wall, EE, 1996
)
0.49
"The two dosage regimens were equally efficient for the relief of angina pectoris without development of tolerance."( Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group.
Cleophas, TJ; Niemeyer, MC; van der Meulen, J; van der Wall, EE, 1996
)
0.29
"(1) Starting on a low dosage was associated with a reduced frequency and severity of headache and did not notably influence the beneficial effect on angina pectoris."( Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group.
Cleophas, TJ; Niemeyer, MC; van der Meulen, J; van der Wall, EE, 1996
)
0.29
" The differences in the effects of the two dosage forms of IS-5-MN on painless ischemia may be explained by limited coronary reserves of anginal patients."( [The effect on painful and silent myocardial ischemia of the preparations Efox and Efox Long in patients with stenocardia of effort].
Belousov, IuB; Egorova, NA; Karasev, AV; Upnitskiĭ, AA, 1997
)
0.3
"The effect of extended-release isosorbide mononitrate (ER-ISMN) on exercise tolerance 1 hour after dosing was compared with that of placebo in a multicenter, randomized, double-blind study of 151 patients with stable effort-induced angina."( Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group.
Glasser, SP, 1997
)
0.3
"A straightforward quantitative method for gas chromatography-mass spectrometry determination of isosorbide 5-mononitrate (IS5MN) and its related impurities such as isosorbide (IS), isosorbide diacetate (ISDA) and isosorbide 2-acetate-5-nitrate (IS2A5N) in raw materials as well as in dosage formulations is developed."( Gas chromatography-mass spectrometry determination of isosorbide 5-mononitrate and related impurities in raw materials and dosage formulations.
Agbaba, D; Comor, JJ; Marinković, VD; Milojković, SS; Nedeljković, JM; Zivanov-Stakić, D, 1997
)
0.3
"In patients with chronic stable angina, IMD provides effective antianginal prophylaxis for up to 12 hours and does not seem to be associated with rebound phenomena at the end of the dosage interval."( Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
Gunasekara, NS; Noble, S, 1999
)
0.3
" There is substantial evidence that this can be prevented by an adequate nitrate-free or nitrate-low period during each 24 h dosing interval."( Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
Waller, DG, 1999
)
0.3
"High-dosage nitrates are more effective for the management of anginal symptoms but produce more adverse effects, including development of tolerance and the zero-hour effect (rebound angina at the end of the dosing interval)."( Comparison of 50-mg and 100-mg sustained-release isosorbide mononitrate in the treatment of stable angina pectoris: effects on quality-of-life indices. Dutch Mononitrate Quality of Life (DUMQOL) Study Group.
Buunk, BP; Cleophas, TJ; Niemeyer, MG; van der Sluijs, H; van der Wall, EE; Zwinderman, AH, 1999
)
0.3
"On average, we observed a moderate increase of Q one hour after ISMO dosing (+8."( Human retinal hemodynamics following administration of 5-isosorbide mononitrate.
DuPont, J; Grunwald, JE; Iannaccone, AE, 2000
)
0.31
"Asymmetric dosage regimens of isosorbide mononitrate provide better antianginal efficacy and quality of life in patients with stable angina pectoris than the daily administration of multiple small doses of the compound."( Independent determinants of the efficacy of nitrate therapy.
Cleophas, TJ; Jansen, R; Niemeyer, MG; Zwinderman, AH, 2000
)
0.31
"Domestic 5-IM sustained-release capsule showed bioequivalence compared with the imported capsule and provided the same nitrate-low interval in the latter part of the 24-h dosing interval."( Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men.
Ding, Y; Huang, DK; Jiang, ZH; Luo, JP; Luo, WX; Peng, JH; Qiu, J; Shen, JP; Sheng, LS; Zhang, YD, 1999
)
0.3
" Data including age, gender, type of medication, dosage and cost were extracted from the database of the largest health maintenance organisation (HMO) in Israel."( The prescription pattern of oral nitrates in coronary artery disease. Appropriateness and cost considerations.
Aviram, EE; Elhayani, A; Galai, N; Lifshitz, M; Paran, E; Peled, R; Reuveni, H; Sherf, M, 2001
)
0.31
"The influences of food, tablet splitting, and fractional dosing on the pharmacokinetics of a new controlled-release double-scored tablet containing 60 mg isosorbide-5-mononitrate (Monoket Multitab) were investigated in healthy male volunteers."( Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
Acerbi, D; De Bruyn, S; Deroubaix, X; Jeanbaptiste, B; Lebacq, E; Nollevaux, F; Poli, G; Stockis, A, 2002
)
0.76
"A reversed phase HPLC method using C(18) column was developed for the quantitative determination of isosorbide mononitrate (IMN) in the bulk material and extended release dosage forms."( A validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations.
Garg, S; Verma, RK, 2002
)
0.31
" In contrast, it is unclear whether vascular superoxide increases during eccentric administration of oral nitrates, which is a widely used therapeutic dosing regimen."( Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance.
Kojda, G; Laber, U; Meyer, W; Müllenheim, J; Müller, S, 2003
)
0.32
" Future studies of L-arginine in conjunction with chronic continuous ISMN dosing are warranted."( Interactions of L-arginine, isosorbide mononitrate, and angiotensin II inhibitors on arterial pulse wave.
Barin, ES; Gilfillan, KL; Kaesemeyer, WH; Stokes, GS, 2003
)
0.32
" Each consecutive dosing was separated by a washout period of 7 days."( Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
Cai, L; Chen, J; Gao, KP; Jiang, XG; Lu, W; Shi, ZQ; Zhang, QZ, 2004
)
0.32
" Using electronic measurement, significantly greater adherence to the once daily versus the twice daily nitrate regimen in terms of dosing and timing was found."( Comparison of once daily versus twice daily oral nitrates in stable angina pectoris.
Kardas, P, 2004
)
0.32
" During a 4-hour delay of the regular morning dose of ISMN, mean systolic blood pressure was higher than with the regular ISMN dosing schedule (P<0."( Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension.
Barin, ES; Bune, AJ; Huon, N; Stokes, GS, 2005
)
0.33
" Effects of each nitrate on pulse wave reflection (augmentation index (AIx)), platelet response to adenosine di-phosphate (ADP 1 micromol l(-1)), nitroglycerine (NTG 100 micromol l(-1)) and the non-nitrate NO donor sodium nitroprusside (SNP 10 micromol l(-1)), were measured pre-dose, 4 and 8 h post dose, on three occasions: 1) at the end of a pre-nitrate phase, 2) after dosing for 7 days and 3) following 14 days of full dose therapy with either nitrate."( Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.
Chirkov, YY; Holmes, AS; Horowitz, JD; Pereira, J; Poropat, S; Willoughby, SR, 2005
)
0.33
" Whereas in dippers ACE inhibitors had a super-dipping effect when dosed at night, no consistent difference in BP lowering effect on the 24-hr BP profile was found with calcium channel blockers after morning and evening dosing."( The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man.
Lemmer, B, 2006
)
0.33
" It was concluded that neural network technique could be particularly suitable in the pharmaceutical technology of time-dependent dosage forms where systems were complex and nonlinear relationships often existed between the independent and the dependent variables."( Optimization and evaluation of time-dependent tablets comprising an immediate and sustained release profile using artificial neural network.
Chen, Q; Gan, L; Gan, Y; Ma, S; Xie, H, 2008
)
0.35
" Continuous dosage of nitrates leads to the development of tolerance both to the vascular effects and to the unwanted adverse effect, headache."( Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate.
Christiansen, I; Iversen, HK; Olesen, J; Tfelt-Hansen, P, 2008
)
0.56
" Pharmacokinetic assessments were taken at regular intervals over 24 h after dosing on the last day of each treatment period."( Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Antunes, A; Bartlett, M; Dieterich, HA; Dole, WP; Howard, D; Vaidyanathan, S; Yeh, CM, 2008
)
0.56
" Further trials with adequate PT dosing are required to determine the efficacy of combination BL+PT therapy."( Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices.
Cheung, J; Tandon, P; van Zanten, SV; Zeman, M, 2009
)
0.35
" Seventy-two patients (nitrate group) took isosorbide mononitrate 30 mg daily, titered to a maximal dosage of 120 mg daily for 24 weeks."( Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate.
Li, H; Wang, SX,
)
0.13
"The objective of the present study was to develop a novel in vitro system to simulate the process of dissolution and permeation of oral solid dosage forms in vivo, and to establish a correlation between in vitro permeation and in vivo absorption that could predict the bioavailability (BA) and bioequivalence (BE) of congeneric products."( Study on dissolution and absorption of four dosage forms of isosorbide mononitrate: level A in vitro-in vivo correlation.
Gao, X; Gu, H; He, X; Ji, RF; Li, ZQ; Sun, SJ; Wang, YF; Xu, YY, 2011
)
0.37
" The dosing regimens differed in terms of dose, number of administrations and route of administration in the different trials."( Cervical ripening before first trimester surgical evacuation for non-viable pregnancy.
Grivell, RM; Webber, K, 2015
)
0.42
"A modified in vitro-in vivo correlation (IVIVC) of the oral solid dosage forms has been proposed as a linear correlation between in vitro and in vivo dissolution."( Quantitative Assessment of the in vivo Dissolution Rate to Establish a Modified IVIVC for Isosorbide Mononitrate Tablets.
Cheng, Z; Tan, Y; Wang, L; Zhang, G; Zhang, L, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
nitric oxide donorAn agent, with unique chemical structure and biochemical requirements, which generates nitric oxide.
vasodilator agentA drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
nitrate esterAny member of the class of nitrates resulting from the esterification of nitric acid with an alcohol.
glucitol derivativeA hexitol derivative that is formally obtained from a glucitol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (73)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID745128Vasorelaxant activity against acetylcholine-induced contraction in rat aortic rings at 100 uM2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer's disease agents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID445826Inhibition of human carbonic anhydrase 1 up to 100 uM by CO2 hydrase stopped flow assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID445832Vasorelaxant activity against methoxiamin-induced contraction in rabbit aortic ring2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID598020Inhibition of carbomer-induced ocular hypertension in New Zealand rabbits assessed as time for maximal IOP lowering efficacy at 2 % in 50 uL administered into eye after 2 to 3 weeks of carbomer challenge2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action.
AID747766Induction of nitrite release in phosphate buffer at pH 7.4 at 10'-4 M after 4 hrs by Griess method2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
NO-donating tacrine derivatives as potential butyrylcholinesterase inhibitors with vasorelaxation activity.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID424016Vasodilation activity in rabbit aortic rings assessed as relaxation of 3 uM methoxamine-induced contraction in presence of 10 uM guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis of novel nitric oxide (NO)-releasing esters of timolol.
AID747768Selectivity ratio of IC50 for electric eel AChE to IC50 for equine serum BChE2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
NO-donating tacrine derivatives as potential butyrylcholinesterase inhibitors with vasorelaxation activity.
AID1908169Induction of oxidative stress in HUVEC cells assessed as increase in intracellular ROS level at 5 uM incubated for 24 hrs by DCHF staining based inverted microscopic analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Design, synthesis and biological evaluation of novel nitric oxide donors with antioxidative activity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID445831Solubility at pH 62009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID445829Reduction of intraocular pressure in normotensive New Zealand white rabbit at 55 mM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
AID424015Vasodilation activity in rabbit aortic rings assessed as relaxation of 3 uM methoxamine-induced contraction in absence of guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis of novel nitric oxide (NO)-releasing esters of timolol.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID745127Chemical stability of the compound in phosphate buffer assessed as nitrite release after 4 hrs at pH 7.4 by Griess method2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer's disease agents.
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID598018Antiglaucoma activity in New Zealand rabbits assessed as inhibition of carbomer-induced ocular hypertension at 2 % in 50 uL administered into eye after 2 to 3 weeks of carbomer challenge (Rvb = 35.3 +/- 1.2 mmHg)2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action.
AID1908172Vasodilation activity in C57BL/6 mouse thoracic aorta assessed as relaxation of phenylephrine-induced contractions at 5 to 50 uM2022European journal of medicinal chemistry, Jun-05, Volume: 236Design, synthesis and biological evaluation of novel nitric oxide donors with antioxidative activity.
AID445827Inhibition of human carbonic anhydrase 2 up to 100 uM by CO2 hydrase stopped flow assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID445828Inhibition of human carbonic anhydrase 4 up to 100 uM by CO2 hydrase stopped flow assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1908168Effect on intracellular NO production in HUVEC cells assessed as increase in NO level at 5 uM incubated for 24 hrs by inverted microscopic analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Design, synthesis and biological evaluation of novel nitric oxide donors with antioxidative activity.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409946Inhibition of human recombinant MAOB at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID445830Reduction of intraocular pressure in normotensive New Zealand white rabbit assessed as time to reach maximal difference at 55 mM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
AID747769Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate after 5 mins by Ellman's method2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
NO-donating tacrine derivatives as potential butyrylcholinesterase inhibitors with vasorelaxation activity.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID747770Inhibition of electric eel AChE using acetylthiocholine iodide as substrate after 5 mins by Ellman's method2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
NO-donating tacrine derivatives as potential butyrylcholinesterase inhibitors with vasorelaxation activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (848)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990219 (25.83)18.7374
1990's258 (30.42)18.2507
2000's239 (28.18)29.6817
2010's106 (12.50)24.3611
2020's26 (3.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.68 (24.57)
Research Supply Index7.13 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index68.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials369 (41.84%)5.53%
Reviews72 (8.16%)6.00%
Case Studies23 (2.61%)4.05%
Observational0 (0.00%)0.25%
Other418 (47.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (66)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nitrate Effect on Exercise Capacitance and Hemodynamic Profile Prior to Fontan Failure [NCT04297241]Phase 220 participants (Actual)Interventional2019-12-12Completed
Effect of Nicorandil, Diltiazem or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts - A Pilot Randomized Controlled Trial [NCT04310995]Phase 4150 participants (Actual)Interventional2020-06-02Completed
The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache. Development of a Pragmatic Migraine Model [NCT02485340]30 participants (Actual)Interventional2015-04-30Completed
Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor in Term or Post Term Pregnancies in Females With Pre-labor Rupture of Membranes [NCT03665779]Phase 3140 participants (Actual)Interventional2018-08-01Completed
A Randomized, Open Label, Balanced, Single Dose, 3-way Crossover Bioequivalence Study of Two Isosorbide -5 -Mononitrate Extended -Release Tablets 40 mg and ISMO Retard 40 mg Under Fed Conditions in Healthy Subjects [NCT03557580]Phase 112 participants (Actual)Interventional2018-04-17Completed
A Randomized, Open-label, One Dose, 2-way Crossover Study to Evaluate the Bioequivalence of Elantan SR* 60 mg in Comparison With Imdur SR* 60 mg Under Fasted and Fed Conditions in Healthy Korean Male Subjects (*Sustained Release) [NCT02101710]Phase 160 participants (Actual)Interventional2011-06-30Completed
Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor: A Randomized Controlled Trial [NCT03523754]Phase 1/Phase 250 participants (Anticipated)Interventional2018-01-01Active, not recruiting
Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy [NCT03072082]Phase 4440 participants (Anticipated)Interventional2017-06-30Not yet recruiting
Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor [NCT03544606]Phase 3140 participants (Actual)Interventional2019-01-01Completed
Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study to Investigate Safety, Tolerability and Blood Pressure of 2.5 mg, 5.0 mg and 10 mg Vericiguat Each Given Over 14 ± 3 Days Together With Isosorbite Mononitrate (ISMN) 60 mg E [NCT03255512]Phase 141 participants (Actual)Interventional2017-08-17Completed
Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography. [NCT02258620]442 participants (Actual)Interventional2013-06-30Completed
A Four-arm, Single Dose, Two-Period, Pharmacokinetic Study of BiDil SR and IR Capsules and Commercial BiDil Tablets [NCT01587313]Phase 136 participants (Actual)Interventional2012-04-30Completed
Efficacy of Intravaginal Administration of Isosorbide Mononitrate Together With Misoprostol Versus Misoprostol Alone in Induction of Labor in Postdate Women [NCT03854383]Phase 2100 participants (Anticipated)Interventional2019-03-03Recruiting
Randomized Controlled Trial of Nitric-oxide Donor (NOD) Isosorbide Mononitrate (IMN) Versus Placebo for Induction of Labor in Pregnancies Complicated by Preeclampsia [NCT03171480]Phase 4176 participants (Actual)Interventional2017-10-30Completed
Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin. [NCT02488642]Phase 460 participants (Actual)Interventional2008-05-31Completed
Renin-Angiotensin Aldosterone System and Fibrinolysis(RAAS) Interaction in Humans- Specific Aim 3 [NCT00685945]24 participants (Actual)Interventional2007-12-31Completed
Effect of Adding Vaginal Isosorbide Mononitrate to Misoprostol Prior to Intrauterine Device Insertion in Women Delivered Only by Elective Cesarean Section: a Randomized Double-blind Controlled Clinical Trial [NCT03587077]113 participants (Anticipated)Interventional2018-09-30Not yet recruiting
The Effect of Isosorbide Diesters Based Moisturizer on Skin Health [NCT04831892]34 participants (Actual)Interventional2021-04-12Completed
Open Monocentric Clinical Study for the Evaluation of Efficacy and Safety of 20 mg Monocordil Tablets Manufactured by Laboratórios Baldacci in Patients With Stable Angina [NCT02152579]Phase 386 participants (Anticipated)Interventional2014-07-31Not yet recruiting
Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial [NCT05276219]Phase 41,104 participants (Anticipated)Interventional2023-09-14Recruiting
Misoprostol Plus Isosorbide Mononitrate Versus Misoprostol For Termination Of Anembryonic Pregnancy [NCT02573051]Phase 2108 participants (Anticipated)Interventional2015-06-30Recruiting
Endoscopic Variceal Ligation Plus Propranolol And Isosorbide Mononitrate Versus Endoscopic Variceal Ligation Alone For Secondary Prophylaxis Of Variceal Bleeding: A Randomized Controlled Trial [NCT00766805]177 participants (Actual)Interventional2002-10-31Completed
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With Unexplained Recurrent Pregnancy Loss [NCT05341856]Early Phase 160 participants (Anticipated)Interventional2022-05-01Not yet recruiting
Misoprostol Versus Effox (Individually or in Combination) as Cervical Ripening Agent Prior to 1st Trimesteric Surgical Evacuation [NCT02738177]Phase 290 participants (Anticipated)Interventional2015-11-30Recruiting
A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M [NCT03514108]Phase 41,500 participants (Anticipated)Interventional2018-03-01Recruiting
Treatment of Orthostatic Intolerance [NCT00262470]Phase 1/Phase 2150 participants (Anticipated)Interventional1997-04-30Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Evaluate the Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis in Obese Patients With Hypertension [NCT00871871]Phase 164 participants (Actual)Interventional2009-03-31Completed
Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects [NCT00810381]14 participants (Actual)Interventional1999-01-31Completed
Pain Perception, Headache Provocation and Multiomics of People Who Are Unable to Have Headache [NCT04217668]58 participants (Actual)Interventional2019-12-02Completed
Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction [NCT01516346]Phase 244 participants (Actual)Interventional2012-01-31Completed
Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and Clinical Course of Coronary Heart Disease [NCT03011775]Phase 443 participants (Actual)Interventional2012-11-30Completed
[NCT00000478]Phase 30 participants Interventional1990-11-30Completed
Targeting Wave Reflections to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function in Hypertension [NCT01961453]Phase 20 participants (Actual)Interventional2013-08-31Withdrawn(stopped due to Funding)
Comparison of Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in Patients With Acute Decompensated Heart Failure: A Randomized Controlled Trial [NCT02649998]0 participants (Actual)Interventional2017-01-31Withdrawn(stopped due to Lack of funding)
Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. [NCT02011620]Phase 40 participants (Actual)Interventional2014-10-31Withdrawn(stopped due to The sponsor was no longer in a position to sponsor a CTIMP. Study did not open.)
the Effect of Vaginal Isosorbide Mononitrate Administration in Reducing Pain During Cooper Intrauterine Device Insertion in Nulliparous Women : a Randomized Controlled Trial [NCT04312048]Phase 3110 participants (Actual)Interventional2020-04-15Completed
Safety and Efficacy of the Effect of Isosorbide Mononitrate in Reducing Pain During Levonorgestrel-releasing Intrauterine Device Insertion in Adolescents and Young Women [NCT04311658]Phase 388 participants (Anticipated)Interventional2020-03-30Not yet recruiting
Chinese People's Liberation Army General Hospital [NCT02718521]400 participants (Anticipated)Interventional2016-03-31Active, not recruiting
Nitric Oxide Donors for Treatment of Isolated Oligohydramnios: A Pilot Study [NCT02712125]Phase 2/Phase 3100 participants (Actual)Interventional2013-08-31Completed
Pharmacokinetics, Pharmacodynamics and Safety Comparative Trial of Isosorbide Mononitrate Gel in Participants With Anal Fissure and Healthy Volunteers. [NCT02667535]Phase 10 participants (Actual)Interventional2017-07-31Withdrawn(stopped due to Study has been cancelled and it has not been initiated.)
Pain Perception, Headache Provocation and Multiomics of People Who Are Unable to Have Headache [NCT04218760]58 participants (Actual)Interventional2019-10-10Completed
Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial [NCT04661709]Phase 4502 participants (Anticipated)Interventional2021-03-01Not yet recruiting
A Double-Blind, Randomized, Placebo-Controlled, 5-Period Crossover Study to Evaluate the Effects of a Single Dose of Losartan, a Single Dose of Isosorbide Mononitrate (ISMN), and Single Doses of Losartan + ISMN on Central Blood Pressure Measurements in Mi [NCT00943852]Phase 113 participants (Actual)Interventional2006-08-31Completed
An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg [NCT01418534]Phase 10 participants InterventionalCompleted
An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg [NCT01418547]Phase 10 participants InterventionalCompleted
Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. [NCT00450164]Phase 450 participants Interventional2000-11-30Completed
LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease. [NCT03451591]Phase 2/Phase 3363 participants (Actual)Interventional2018-01-08Completed
Open, Randomized, 3 Period Cross-over Design, in Healthy Volunteers to Compare the Pharmacokinetics Profiles of 3 Treatments: ISO 20, IBU 200 and IBU Plus ISO Combinations (200 + 20) Administered Per os as Single Doses [NCT01478022]Phase 112 participants (Actual)Interventional2011-10-31Completed
Phase I Clinical Trial to Evaluate the Pharmacokinetic Profile of a Formulation With Isosorbide Mononitrate 0.5% Gel - Manufactured by Sanus Pharmaceutical Ltda, to Intra Anal Application in Healthy Males and Females' Subjects [NCT04729088]Phase 10 participants (Actual)Interventional2020-12-20Withdrawn(stopped due to The sponsor will no longer develop the experimental drug.)
A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction [NCT01822808]Phase 3500 participants (Anticipated)Interventional2013-01-31Active, not recruiting
A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis [NCT01513070]Phase 4120 participants (Anticipated)Interventional2012-04-30Completed
Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital [NCT01631409]0 participants (Actual)Observational2013-09-30Withdrawn(stopped due to The study has been withdrawn due to organizational problems)
One-year Outcome of Intensive Versus Standard Blood Pressure Treatment in Non-ST Elevation Acute Coronary Syndrome: A Randomised Controlled Trial [NCT02135315]1,500 participants (Actual)Interventional2014-03-31Completed
Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction [NCT02053493]Phase 2110 participants (Actual)Interventional2014-04-30Completed
Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure [NCT02522208]Phase 112 participants (Actual)Interventional2015-09-30Completed
Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers [NCT02789033]Phase 368 participants (Actual)Interventional2015-06-30Completed
Randomized Clinical Trial of Cervical Ripening and Labor Induction Using Stepwise Oral Misoprostol With or Without Intravaginal Isosorbide Mononitrate [NCT00374621]156 participants (Actual)Interventional2006-09-30Completed
Preventing Cognitive Decline and Dementia From Cerebral Small Vessel Disease [NCT02481323]Phase 257 participants (Actual)Interventional2016-03-31Completed
Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate to Prevent Post-ERCP Pancreatitis: a Multicentre, Non-inferiority, Double-blind, Randomised Trial [NCT04425993]2,700 participants (Actual)Interventional2020-07-01Active, not recruiting
Isosorbide Mononitrate and Misoprostol in Induction of Labour [NCT04482881]Early Phase 1130 participants (Anticipated)Interventional2020-07-21Not yet recruiting
Non-inferiority Trial Comparing Pharmacological Prevention Alone Versus Pancreatic Stents Plus Pharmacological Prevention to Prevent Post-ERCP Pancreatitis [NCT02368795]400 participants (Anticipated)Interventional2015-02-28Recruiting
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury [NCT04051957]Phase 29 participants (Actual)Interventional2019-09-26Terminated(stopped due to Delays due to COVID and loss of research coordinator.)
Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy [NCT03072121]Phase 4440 participants (Anticipated)Interventional2017-06-30Not yet recruiting
Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study [NCT02343393]Phase 3100 participants (Anticipated)Interventional2015-01-31Recruiting
Measuring Response of Adding Isosorbide Mononitrate to Misoprostol in Induction of Second Trimester Abortion [NCT03407521]Phase 460 participants (Actual)Interventional2017-04-12Completed
Prospective Randomized Vehicle-Controlled, Double-Blind Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal [NCT05688735]40 participants (Anticipated)Interventional2023-04-20Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00685945 (3) [back to overview]Net Glucose Uptake
NCT00685945 (3) [back to overview]Net Tissue-type Plasminogen Activator (t-PA) Release
NCT00685945 (3) [back to overview]Forearm Blood Flow (FBF)
NCT00871871 (7) [back to overview]Part II: Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady-state
NCT00871871 (7) [back to overview]Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants Who Had Normal Glucose Tolerance (NGT)
NCT00871871 (7) [back to overview]Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Fasting Glucose (IFG)
NCT00871871 (7) [back to overview]Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT)
NCT00871871 (7) [back to overview]Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Fasting Glucose (IFG)
NCT00871871 (7) [back to overview]Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Glucose Tolerant (IGT)
NCT00871871 (7) [back to overview]Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Normal Glucose Tolerant (NGT)
NCT00943852 (2) [back to overview]Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg
NCT00943852 (2) [back to overview]Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo
NCT01516346 (5) [back to overview]Early Diastolic Mitral Annular Velocity
NCT01516346 (5) [back to overview]LV Mass
NCT01516346 (5) [back to overview]Myocardial Extracellular Volume Fraction
NCT01516346 (5) [back to overview]Quality of Life (Kansas City Cardiomyopathy Questionnaire Score)
NCT01516346 (5) [back to overview]Wave Reflection Magnitude
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Area Under the Curve (Phase II)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Area Under the Curve (Phase I)
NCT02053493 (17) [back to overview]Borg Score During 6 Minute Walk Test (Phase II)
NCT02053493 (17) [back to overview]Borg Score During 6 Minute Walk Test (Phase I)
NCT02053493 (17) [back to overview]Arbitrary Accelerometry Units (AAU) (Phase II)
NCT02053493 (17) [back to overview]Arbitrary Accelerometry Units (AAU) (Phase I)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Hours Active Per Day (Phase I)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Hours Active Per Day (Phase II)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Slope of Daily Average (Phase I)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Slope of Daily Average (Phase II)
NCT02053493 (17) [back to overview]Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase I)
NCT02053493 (17) [back to overview]Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase II)
NCT02053493 (17) [back to overview]N-terminal Pro-B-type Natriuretic Peptide Level (Phase I)
NCT02053493 (17) [back to overview]N-terminal Pro-B-type Natriuretic Peptide Level (Phase II)
NCT02053493 (17) [back to overview]Six Minute Walk Distance (Phase I)
NCT02053493 (17) [back to overview]Six Minute Walk Distance (Phase II)
NCT02053493 (17) [back to overview]Patient Preference for Isosorbide Mononitrate Treatment at the End of Study.
NCT02789033 (1) [back to overview]Biopsies
NCT03011775 (17) [back to overview]Safety and Tolerability 3
NCT03011775 (17) [back to overview]Safety and Tolerability 4
NCT03011775 (17) [back to overview]Systemic Inflammation Level
NCT03011775 (17) [back to overview]Thickness of the Intima-media Complex
NCT03011775 (17) [back to overview]Lipid Metabolism 2
NCT03011775 (17) [back to overview]Сardiovascular Death
NCT03011775 (17) [back to overview]Cardiovascular Hospitalization
NCT03011775 (17) [back to overview]Carotic Atherosclerotic Lesions
NCT03011775 (17) [back to overview]Coronary Artery Bypass [Coronary Revascularization]
NCT03011775 (17) [back to overview]Diameter of Stenosis [Carotic Atherosclerotic Lesions]
NCT03011775 (17) [back to overview]Level of Insulin Resistance 1
NCT03011775 (17) [back to overview]Level of Insulin Resistance 2
NCT03011775 (17) [back to overview]Lipid Metabolism 1
NCT03011775 (17) [back to overview]Lipid Metabolism 3
NCT03011775 (17) [back to overview]Percutaneous Coronary Intervention [Coronary Revascularization]
NCT03011775 (17) [back to overview]Safety and Tolerability 1
NCT03011775 (17) [back to overview]Safety and Tolerability 2
NCT03171480 (2) [back to overview]Placental Abruption, Use of IV Antihypertensive Drug, Maternal Hypotension, Uterine Hyperstimulation and Meconium Stained Fluid
NCT03171480 (2) [back to overview]Cesarean Delivery Rate
NCT04051957 (18) [back to overview]Number of Participants With a Reduction in UPC of > 500 mg/Day From That Measured Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With a Reduction in UPC of > 500 mg/Day From That Measured Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With a Reduction in Urine Protein Creatinine Ratio (UPC) of > 500 mg/Day From That Measured Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Maximal Exercise Capacity VO2 Max
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Maximal Exercise Capacity Respiratory Rate Response
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Maximal Exercise Capacity Heart Rate Response
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Liver Stiffness Levels
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Central Venous Pressure
NCT04297241 (6) [back to overview]Number of Participants Who Experience an Adverse Reaction to the Study Medication During the Study Enrollment Period.

Net Glucose Uptake

Individual net reuptake rates at each time point were calculated by the following formula: net uptake = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of glucose in the brachial vein and artery, respectively. (NCT00685945)
Timeframe: At baseline and after maximum dose of bradykinin

,,,
Interventionmicrogram/min/100ml (Mean)
Net glucose uptake (bradykinin 0 ng/min)Net glucose uptake (bradykinin 200 ng/min)
Control-79.95-319.85
Isosorbide + L-NMMA + Control-71.4-163.233
L-NMMA + Control-74.36-142.86
Sildenafil + L-NMMA + Control-67.3-125.32

[back to top]

Net Tissue-type Plasminogen Activator (t-PA) Release

Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively. (NCT00685945)
Timeframe: During and after each study drug administration

,,,
Interventionng/min/100ml (Mean)
Net t-PA release (bradykinin 0ng/min)Net t-PA release (bradykinin 50ng/min)Net t-PA release (bradykinin 100ng/min)Net t-PA release (bradykinin 200ng/min)
Control0.241.0211.8130.03
Isosorbide + L-NMMA + Control-0.383.1415.9045.32
L-NMMA + Control0.593.6522.1039.90
Sildenafil + L-NMMA + Control0.292.4618.4837.39

[back to top]

Forearm Blood Flow (FBF)

Forearm blood flow was measured by strain gauge plethysmography (NCT00685945)
Timeframe: During and after each study drug administration

,,,
Interventionml/min/100ml (Mean)
FBF (bradykinin 0 ng/min)FBF (bradykinin 50ng/min)FBF (bradykinin 100ng/min)FBF (bradykinin 200 ng/min)
Control4.037.0213.1717.74
Isosorbide + L-NMMA + Control2.184.736.839.91
L-NMMA + Control2.365.168.6711.21
Sildenafil + L-NMMA + Control2.805.879.1312.92

[back to top]

Part II: Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady-state

Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Intervention(mg/kg/minute)/(µIU/mL) (Least Squares Mean)
Isosorbide Mononitrate (ISMN)0.040
Isosorbide Mononitrate (ISMN) Placebo0.044

[back to top]

Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants Who Had Normal Glucose Tolerance (NGT)

Steady state was defined as 90-120 minutes post-dose. NGT participants (FPG <100 mg/dL & 2 hour plasma glucose (PG) <140 mg/dL during a 75g oral glucose tolerance test (OGTT) at screening) were neither Impaired Glucose Tolerant (IGT) nor Impaired Fasting Glucose (IFG). IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening. IFG was defined as FPG between 100 and 125 mg/dL at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Interventionng/minute (Least Squares Mean)
Hydrochlorothiazide (HCTZ)5.54
Hydrochlorothiazide (HCTZ) Placebo5.01

[back to top]

Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Fasting Glucose (IFG)

Steady state was defined as 90-120 minutes post-dose. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Interventionng/minute (Least Squares Mean)
Hydrochlorothiazide (HCTZ)5.60
Hydrochlorothiazide (HCTZ) Placebo4.50

[back to top]

Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT)

Steady state was defined as 90-120 minutes post-dose. IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Interventionng/minute (Least Squares Mean)
Hydrochlorothiazide (HCTZ)3.44
Hydrochlorothiazide (HCTZ) Placebo3.55

[back to top]

Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Fasting Glucose (IFG)

Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Intervention(mg/kg/minute)/(µIU/mL) (Least Squares Mean)
Hydrochlorothiazide (HCTZ)0.038
Hydrochlorothiazide (HCTZ) Placebo0.037

[back to top]

Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Glucose Tolerant (IGT)

Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Intervention(mg/kg/minute)/(µIU/mL) (Least Squares Mean)
Hydrochlorothiazide (HCTZ)0.061
Hydrochlorothiazide (HCTZ) Placebo0.045

[back to top]

Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Normal Glucose Tolerant (NGT)

Steady state was defined as 90-120 minutes post-dose. The ratio was the measure of the quantity of glucose disposed per unit of plasma insulin concentration (PIC). Approximate PIC was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals, time = 90, 100, 110, and 120 minutes. NGT participants (FPG <100 mg/dL & 2 hour PG <140 mg/dL during a 75g OGTT at screening) were neither IGT nor IFG at screening. IGT - defined as a 2 hour PG >= 140 and <= 199 mg/dL during a 75g OGTT at screening. IFG - defined as FPG between 100 and 125 mg/dL at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Intervention(mg/kg/minute)/(µIU/mL) (Least Squares Mean)
Hydrochlorothiazide (HCTZ)0.045
Hydrochlorothiazide (HCTZ) Placebo0.042

[back to top]

Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg

The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline. (NCT00943852)
Timeframe: Baseline and 10 hours postdose

InterventionPercent Change (Least Squares Mean)
Losartan 100 mg + ISMN 60 mg-24.9
Losartan 100 mg-1.8

[back to top]

Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo

"The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P =~pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline." (NCT00943852)
Timeframe: Baseline and 10 hours postdose

InterventionPercent Change (Least Squares Mean)
Losartan 100 mg + ISMN 60 mg-24.9
Placebo-1.3

[back to top]

Early Diastolic Mitral Annular Velocity

Diastolic mitral annular velocity measured at the basal septal mitral annulus (NCT01516346)
Timeframe: 24 weeks

Interventioncm/s (Mean)
Isosorbide Dinitrate6.8
Isosorbide Dinitrate + Hydralazine7.3
Placebo6.5

[back to top]

LV Mass

LV mass measured by MRI, in grams normalized to height in meters raised to the 1.7 power (m^1.7) (NCT01516346)
Timeframe: 24 weeks

Interventiongrams / meters ^1.7 (Mean)
Isosorbide Dinitrate68.2
Isosorbide Dinitrate + Hydralazine66.2
Placebo67.2

[back to top]

Myocardial Extracellular Volume Fraction

Myocardial extracellular volume, expressed as percent of total tissue volume, measured by MRI (T1 mapping pre and post-gadolinium administration) (NCT01516346)
Timeframe: 24 weeks

InterventionPercentage (Mean)
Isosorbide Dinitrate29.0
Isosorbide Dinitrate + Hydralazine31.3
Placebo29.5

[back to top]

Quality of Life (Kansas City Cardiomyopathy Questionnaire Score)

Quality of life, assessed with the Kansas City cardiomyopathy questionnaire (overall summary score, which ranges from 0 to 100). Higher values imply better quality of life. (NCT01516346)
Timeframe: 24 weeks

InterventionPoints on a scale (Mean)
Isosorbide Dinitrate62.1
Isosorbide Dinitrate + Hydralazine44.9
Placebo62.1

[back to top]

Wave Reflection Magnitude

The dimensionless ratio of backward (reflected) to forward wave amplitude. Higher values imply more wave reflection. (NCT01516346)
Timeframe: 24 weeks

Interventiondimensionless ratio (Mean)
Isosorbide Dinitrate0.38
Isosorbide Dinitrate + Hydralazine0.44
Placebo0.37

[back to top]

Improvement in Daily Activity - Area Under the Curve (Phase II)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Area under the curve (AUC) of arbitrary accelerometry units during study drug administration. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. Area under the curve is defined as ((7*average acceleromtery units/day during 30 mg) + (7*average acceleromtery units/day during 60 mg) + (14*average acceleromtery units/day during 120 mg))/28 (NCT02053493)
Timeframe: 9-12 weeks

Interventionaccelerometry units (Mean)
Isosorbide Mononitrate Crossover to Placebo9146.5
Placebo Crossover to Isosorbide Mononitrate9325.9

[back to top]

Improvement in Daily Activity - Area Under the Curve (Phase I)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Area under the curve (AUC) of arbitrary accelerometry units during study drug administration. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. Area under the curve is defined as ((7*average acceleromtery units/day during 30 mg) + (7*average acceleromtery units/day during 60 mg) + (14*average acceleromtery units/day during 120 mg))/28 (NCT02053493)
Timeframe: 3-6 weeks

Interventionaccelerometry units (Mean)
Isosorbide Mononitrate Crossover to Placebo9621.4
Placebo Crossover to Isosorbide Mononitrate9714.0

[back to top]

Borg Score During 6 Minute Walk Test (Phase II)

To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo. The Borg Scale consists of scale range of 0 to 10 (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness). Lower values are considered to be better than higher values. (NCT02053493)
Timeframe: Week 13

Interventionunits on a scale (Mean)
Isosorbide Mononitrate Crossover to Placebo3.8
Placebo Crossover to Isosorbide Mononitrate3.8

[back to top]

Borg Score During 6 Minute Walk Test (Phase I)

To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo. The Borg Scale consists of scale range of 0 to 10 (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness). Lower values are considered to be better than higher values. (NCT02053493)
Timeframe: Week 7

Interventionunits on a scale (Mean)
Isosorbide Mononitrate Crossover to Placebo4.1
Placebo Crossover to Isosorbide Mononitrate4.0

[back to top]

Arbitrary Accelerometry Units (AAU) (Phase II)

To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day averaged arbitrary accelerometry units in comparison to placebo. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. (NCT02053493)
Timeframe: 11-12 weeks

Interventionaccelerometry units (Mean)
Isosorbide Mononitrate Crossover to Placebo8824
Placebo Crossover to Isosorbide Mononitrate8900

[back to top]

Arbitrary Accelerometry Units (AAU) (Phase I)

To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day averaged arbitrary accelerometry units in comparison to placebo. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. (NCT02053493)
Timeframe: 5-6 weeks

Interventionaccelerometry units (Mean)
Isosorbide Mononitrate Crossover to Placebo9370
Placebo Crossover to Isosorbide Mononitrate9538

[back to top]

Improvement in Daily Activity - Hours Active Per Day (Phase I)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Hours active per day during maximal dose of study drug (NCT02053493)
Timeframe: 5-6 weeks

InterventionHours/day (Mean)
Isosorbide Mononitrate Crossover to Placebo9.4
Placebo Crossover to Isosorbide Mononitrate9.1

[back to top]

Improvement in Daily Activity - Hours Active Per Day (Phase II)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Hours active per day during maximal dose of study drug (NCT02053493)
Timeframe: 11-12 weeks

InterventionHours/day (Mean)
Isosorbide Mononitrate Crossover to Placebo9.4
Placebo Crossover to Isosorbide Mononitrate8.8

[back to top]

Improvement in Daily Activity - Slope of Daily Average (Phase I)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Slope of daily averaged arbitrary accelerometry units during study drug administration. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. (NCT02053493)
Timeframe: 3-6 weeks

Interventionaccelerometry units/day (Mean)
Isosorbide Mononitrate Crossover to Placebo-3.4
Placebo Crossover to Isosorbide Mononitrate-1.3

[back to top]

Improvement in Daily Activity - Slope of Daily Average (Phase II)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Slope of daily averaged arbitrary accelerometry units during study drug administration. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. (NCT02053493)
Timeframe: 9-12 weeks

Interventionaccelerometry units/day (Mean)
Isosorbide Mononitrate Crossover to Placebo2.6
Placebo Crossover to Isosorbide Mononitrate-3.9

[back to top]

Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase I)

To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life). (NCT02053493)
Timeframe: Week 7

Interventionunits on a scale (Mean)
Isosorbide Mononitrate Crossover to Placebo57.3
Placebo Crossover to Isosorbide Mononitrate64.2

[back to top]

Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase II)

To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo. • The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life).Higher values of the overall KCCQ score are considered to be better than lower values. (NCT02053493)
Timeframe: Week 13

Interventionunits on a scale (Mean)
Isosorbide Mononitrate Crossover to Placebo59.1
Placebo Crossover to Isosorbide Mononitrate61.6

[back to top]

N-terminal Pro-B-type Natriuretic Peptide Level (Phase I)

To evaluate whether isosorbide mononitrate improves natriuretic peptide levels in comparison to placebo (NCT02053493)
Timeframe: Week 7

Interventionpg/mL (Mean)
Isosorbide Mononitrate Crossover to Placebo513.0
Placebo Crossover to Isosorbide Mononitrate542.4

[back to top]

N-terminal Pro-B-type Natriuretic Peptide Level (Phase II)

To evaluate whether isosorbide mononitrate improves natriuretic peptide levels in comparison to placebo (NCT02053493)
Timeframe: Week 13

Interventionpg/mL (Mean)
Isosorbide Mononitrate Crossover to Placebo466.1
Placebo Crossover to Isosorbide Mononitrate573.3

[back to top]

Six Minute Walk Distance (Phase I)

To evaluate whether isosorbide mononitrate (ISMN) improves functional capacity by 6 minute walk distance in comparison to placebo. (NCT02053493)
Timeframe: Week 7

Interventionmeters (Mean)
Isosorbide Mononitrate Crossover to Placebo307.8
Placebo Crossover to Isosorbide Mononitrate327.1

[back to top]

Six Minute Walk Distance (Phase II)

To evaluate whether isosorbide mononitrate (ISMN) improves functional capacity by 6 minute walk distance in comparison to placebo. (NCT02053493)
Timeframe: Week 13

Interventionmeters (Mean)
Isosorbide Mononitrate Crossover to Placebo321.3
Placebo Crossover to Isosorbide Mononitrate329.7

[back to top]

Patient Preference for Isosorbide Mononitrate Treatment at the End of Study.

Self reported participant preference for study period 1 vs. study period 2. (NCT02053493)
Timeframe: Week 13

,
Interventionparticipants (Number)
Phase1Phase2No Preference
Isosorbide Mononitrate Crossover to Placebo141816
Placebo Crossover to Isosorbide Mononitrate142419

[back to top]

Biopsies

Histological changes in ulcers (NCT02789033)
Timeframe: 75 days

,,,
InterventionUI/dL (Mean)
α-smooth muscle actinVon Willebrand Factorvascular endothelial growth factor-Adesmin
Active Comparator: Chitosan2.462.382.232.3
Active Comparator: Isosorbide Dinitrate Spray2.642.282.62.5
Combination: IDS and Chitosan2.562.312.432.6
Placebo Comparator: Placebo2.072.152.072.3

[back to top]

Safety and Tolerability 3

Kidney injury: mean values of the microalbuminuria (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmg/mol (Mean)
Baseline1 year
Pioglitazone + Standard Care31.4431.10
Standard Care41.137.70

[back to top]

Safety and Tolerability 4

Kidneys injury: mean values of creatinine (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionμmol/l (Mean)
Mean values of creatinine in men baselineMean values of creatinine in men in 1 yearMean values of creatinine in women baselineMean values of creatinine in women in 1 year
Pioglitazone + Standard Care105.685.066.872.5
Standard Care102.382.088.277.5

[back to top]

Systemic Inflammation Level

Number of Participants with C-reactive protein level above 3 mg/L (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
BaselineIn 1 year
Pioglitazone + Standard Care1012
Standard Care713

[back to top]

Thickness of the Intima-media Complex

Mean thickness of carotid intima-media complex (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventioncm (Mean)
Mean thickness of the right carotid intima-media baselineMean thickness of the right carotid intima-media in 6 monthMean thickness of the right carotid intima-media in 1 yearMean thickness of the left carotid intima-media baselineMean thickness of the left carotid intima-media in 6 monthMean thickness of the left carotid intima-media in 1 year
Pioglitazone + Standard Care1.081.051.011.11.061.02
Standard Care0.980.971.011.01.000.97

[back to top]

Lipid Metabolism 2

Mean values of the triglyceride levels (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Intervention1 mmol/L (Mean)
Mean values of triglyceride baselineMean values of triglyceride in 6 monthMean values of triglyceride in 1 year
Pioglitazone + Standard Care0.690.720.9
Standard Care0.610.730.7

[back to top]

Сardiovascular Death

Number of Participants with cardiovascular death (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Cardiovascular Hospitalization

Number of Participants with acute coronary syndrome (ACS) or unstable angina (UA) (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Carotic Atherosclerotic Lesions

Number of Participants with presence of atherosclerotic plaque of the intima media of common carotid artery greater than 1.4 mm (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Coronary Artery Bypass [Coronary Revascularization]

Number of Participants with revascularization coronary procedures (coronary artery bypass grafting) (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Diameter of Stenosis [Carotic Atherosclerotic Lesions]

Mean diameters of the stenosis of the right and left common carotid arteries (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmm (Mean)
Mean diameter of the stenosis of the right common carotid artery baselineMean diameter of the stenosis of the right common carotid artery in 1 yearMean diameter of the stenosis of the left common carotid artery baselineMean diameter of the stenosis of the left common carotid artery in 1 year
Pioglitazone + Standard Care9.85.011.64.1
Standard Care8.74.810.15.6

[back to top]

Level of Insulin Resistance 1

Oral glucose tolerance test: number of Participants with impaired glucose tolerance (NCT03011775)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
Number of Participants with glucose level in the range of 7.8 to 11 mmol/L baselineNumber of Participants with glucose level in the range of 7.8 to 11 mmol/L in 6 monthNumber of Participants with glucose level above 11 mmol/L baselineNumber of Participants with glucose level above 11 mmol/L in 6 month
Pioglitazone + Standard Care713105
Standard Care141643

[back to top]

Level of Insulin Resistance 2

Mean levels of blood glucose (NCT03011775)
Timeframe: Baseline and 6 months

,
Interventionmmol/L (Mean)
BaselineIn 6 month
Pioglitazone + Standard Care6.05.97
Standard Care5.95.60

[back to top]

Lipid Metabolism 1

Mean levels of total serum cholesterol (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionmmol / l (Mean)
Mean values of the total cholesterol level baselineMean values of the total cholesterol level in 6 monthMean values of the total cholesterol level in 1 year
Pioglitazone + Standard Care5.274.54.5
Standard Care5.284.34.3

[back to top]

Lipid Metabolism 3

Lipoproteine fractions:mean values of high-density lipoproteins and low density lipoproteins (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmmol/L (Mean)
Mean values of high-density lipoproteins in men baselineMean values of high-density lipoproteins in men in 1 yearMean values of high-density lipoproteins in women baselineMean values of high-density lipoproteins in women in 1 yearMean values of low density lipoproteins in men baselineMean values of low density lipoproteins in men in 1 yearMean values of low density lipoproteins in women baselineMean values of low density lipoproteins in women in 1 year
Pioglitazone + Standard Care0.81.10.91.23.92.94.53.3
Standard Care0.91.01.11.04.43.03.52.7

[back to top]

Percutaneous Coronary Intervention [Coronary Revascularization]

Number of Participants with incidence of percutaneous coronary intervention. (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Safety and Tolerability 1

Liver injury: mean values of ALT (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionunits per liter (U/L) (Mean)
BaselineMean values of ALT in 6 monthsMean values of ALT in 1 year
Pioglitazone + Standard Care23.427.419.9
Standard Care26.926.123.9

[back to top]

Safety and Tolerability 2

Liver injury: mean levels of total bilirubin (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionμmol/l (Mean)
BaselineMean values of total bilirubin in 6 monthMean values of total bilirubin in 1 year
Pioglitazone + Standard Care12.312.415.7
Standard Care10.812.715.0

[back to top]

Placental Abruption, Use of IV Antihypertensive Drug, Maternal Hypotension, Uterine Hyperstimulation and Meconium Stained Fluid

placenta abruption at time of delivery, administration of IV antihypertensive medication for BP >160/110, maternal hypotensive defined as <90/50, Uterine hyperstimulation defined as >3 contractions in 10 minutes and meconium stained amniotic fluid anytime during labor induction/augmentation (NCT03171480)
Timeframe: during the induction of labor till delivery for all outcomes

,
InterventionParticipants (Count of Participants)
AbruptionAnti-hypertensiveshypotensionuterine hyperstimulationMSAF
Monoket Pill029930
Placebo Pill032810

[back to top]

Cesarean Delivery Rate

Rate of cesarean section for those enrolled in study (NCT03171480)
Timeframe: 7 days

InterventionParticipants (Count of Participants)
Monoket Pill29
Placebo22

[back to top]

Number of Participants With a Reduction in UPC of > 500 mg/Day From That Measured Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 2

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate1
Placebo0

[back to top]

Number of Participants With a Reduction in UPC of > 500 mg/Day From That Measured Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 3

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo1

[back to top]

Number of Participants With a Reduction in Urine Protein Creatinine Ratio (UPC) of > 500 mg/Day From That Measured Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 1

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate1
Placebo0

[back to top]

Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 1

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate0
Placebo0

[back to top]

Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 2

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate0
Placebo0

[back to top]

Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 3

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate1
Placebo0

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 1

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate0
Placebo1

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 10

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate2
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 11

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 12

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 2

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate2
Placebo1

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 3

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo1

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 4

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate4
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 5

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate2
Placebo1

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 6

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 7

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 8

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 9

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Effect of Isosorbide Dinitrate on Maximal Exercise Capacity VO2 Max

Obtain estimates of the effect the study medication has on maximal exercise test VO2 max performance in Fontan patients by study participants performing a maximal ramp exercise test on a stationary bike. (NCT04297241)
Timeframe: Baseline and 6 weeks

InterventionmL/min (Median)
Isosorbide Dinitrate - Baseline1086.7
Isosorbide Dinitrate - Post-therapy1151.3

[back to top]

Effect of Isosorbide Dinitrate on Maximal Exercise Capacity Respiratory Rate Response

Obtain estimates of the effect the study medication has on maximal exercise test respiratory rate response in Fontan patients by study participants performing a maximal ramp exercise test on a stationary bike. (NCT04297241)
Timeframe: Baseline and 6 weeks

InterventionRespiratory Exchange Ratio (Median)
Isosorbide Dinitrate - Baseline1.17
Isosorbide Dinitrate - Post-therapy1.19

[back to top]

Effect of Isosorbide Dinitrate on Maximal Exercise Capacity Heart Rate Response

Obtain estimates of the effect the study medication has on maximal exercise test heart rate response in Fontan patients by study participants performing a maximal ramp exercise test on a stationary bike. (NCT04297241)
Timeframe: Baseline and 6 weeks

Interventionbpm (Median)
Isosorbide Dinitrate - Baseline156.6
Isosorbide Dinitrate - Post-therapy164.7

[back to top]

Effect of Isosorbide Dinitrate on Liver Stiffness Levels

Determine effectiveness of study medication on hemodynamic profile by completing baseline and post-study medication liver ultrasound measuring liver stiffness levels by sheer wave speed (m/s). (NCT04297241)
Timeframe: Baseline and 6 weeks

Interventionm/s (Median)
Isosorbide Dinitrate - Baseline2.3
Isosorbide Dinitrate - Post-therapy2.1

[back to top]

Effect of Isosorbide Dinitrate on Central Venous Pressure

Determine effectiveness of study medication on hemodynamic profile by completing baseline and post-study medication maximal exercise tests to measure central venous pressure via IV catheter insertion (NCT04297241)
Timeframe: Baseline and 6 weeks

InterventionmmHg (Median)
Isosorbide Dinitrate - Baseline22.5
Isosorbide Dinitrate - Post-therapy20.6

[back to top]

Number of Participants Who Experience an Adverse Reaction to the Study Medication During the Study Enrollment Period.

Potential adverse side effects of study medication (isosorbide dinitrate) will be monitored throughout study period. Study medication will be titrated to a maximal dose of 30mg dependent on the patient tolerance. Patient tolerance is defined by frequency of known risk factors to the study medication (headaches, hypotension, and syncope). (NCT04297241)
Timeframe: Baseline and 6 weeks

InterventionParticipants (Count of Participants)
Isosorbide Dinitrate16

[back to top]